Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug;9(4):288-294.
doi: 10.1007/s12672-018-0336-7. Epub 2018 Jun 18.

Androgen Receptor and Ki67 Expression and Survival Outcomes in Non-small Cell Lung Cancer

Laurel Grant  1 , Shantanu Banerji  1   2   3 , Leigh Murphy  1   2   3 , David E Dawe  1   2   3 , Craig Harlos  1   2 , Yvonne Myal  1 , Zoann Nugent  2 , Anne Blanchard  1 , Carla R Penner  1 , Gefei Qing  1 , Marshall W Pitz  4   5   6
Affiliations

Androgen Receptor and Ki67 Expression and Survival Outcomes in Non-small Cell Lung Cancer

Laurel Grant et al. Horm Cancer. 2018 Aug.

Abstract

Lung cancer is the most common cause of cancer-related deaths worldwide with non-small cell lung cancer (NSCLC) making up most of these cases. Males have poorer overall survival compared to women following a lung cancer diagnosis. Many studies have focused on the effects of estrogen to explain higher survival rates among women, but few have looked at the effects of androgens. We describe the expression of the androgen receptor (AR) and Ki67 in lung cancer specimens in the Manitoba Tumor Bank (MTB) and correlate these factors with patient outcome. Using the MTB, we performed immunohistochemistry on lung cancer tissue to determine expression of the AR and Ki67. These were then correlated with patient outcome. Of the 136 cases, 55% were female and 55% were adenocarcinoma. AR expression was not independently associated with outcome. Ki67 was associated with a significantly higher hazard ratio for death and recurrence (HR 2.19, 95% CI 1.30-3.70; HR 1.92, 95% CI 1.07-3.46, respectively). AR expression modified the effect of Ki67 on outcome, such that when both were expressed, there was no association with recurrence or survival (HR 2.39, 95% CI 1.31-4.36 for AR- Ki67+ vs HR 1.54, 95% CI 0.44-5.37 for AR+ Ki67+). Ki67 was associated with poorer outcomes alone. AR status alone was not associated with outcome. Although the mechanism remains unclear, AR status seems to negate the association of a high Ki67 and poor outcome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Staining of Ki67 and AR on NSCLC tissue samples. a AR negative. b Ki67 positive. c AR positive. d Ki67 negative
Fig. 2
Fig. 2
Overall survival probability of patients by AR status (a), Ki67 status (b), and both AR and Ki67 status (c)
See this image and copyright information in PMC

References

    1. World Health Organization (2012) Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 2 Aug 2016
    1. Pitz MW, Musto G, Demers AA, Kliewer EV. Survival and treatment pattern of non-small cell lung cancer over 20 years. J Thorac Oncol. 2009;4(3):492–498. doi: 10.1097/JTO.0b013e31819846fb. - DOI - PubMed
    1. Ridge CA, Mcerlean AM, Ginsberg AM. Epidemiology of lung cancer. Semin Interv Radiol. 2013;30(2):93–98. doi: 10.1055/s-0033-1342949. - DOI - PMC - PubMed
    1. Dawe DE, Pond GR, Ellis PM. Assessment of referral and chemotherapy treatment patterns for elderly patients with non small-cell lung cancer. Clin Lung Cancer. 2016;17(6):563–572. doi: 10.1016/j.cllc.2016.05.012. - DOI - PubMed
    1. Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA. 2016;291(14):1763–1768. - PubMed

Publication types